Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
American Sales Company, LLC v. Pfizer, Inc. et al
Case Number:
2:14-cv-00361
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Berger Montague
- Berkowitz Oliver
- Faruqi & Faruqi
- Glasser & Glasser
- Hagens Berman
- Kaufman & Canoles
- Lowenstein Sandler
- Merchant & Gould
- Paul Weiss
- Radice Law Firm
- Taus Cebulash
- White & Case
Companies
Sectors & Industries:
-
April 19, 2018
Pfizer Gets Final Nod On $94M Celebrex Antitrust Settlement
A Virginia federal judge signed off Wednesday on Pfizer's $94 million settlement, including nearly $31 million in legal fees, with drug buyers who said the pharmaceutical giant extended its monopoly over the anti-inflammatory Celebrex by illegally blocking generic competition.
-
January 09, 2018
Hagens Berman, Others Want $31M In Pfizer Celebrex Deal
Hagens Berman Sobol Shapiro LLP, Berger & Montague PC and a handful of other firms on Monday asked a Virginia federal court to grant them about $31 million in fees after reaching a $94 million settlement with Pfizer Inc. over allegations that the company blocked competition for its anti-inflammatory drug Celebrex.
-
November 27, 2017
Pfizer Reaches $94M Settlement Over Celebrex Claims
Pfizer and a class of direct purchasers who allege the drugmaker used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex have told a Virginia federal court that they have reached a $94 million settlement agreement.
-
June 28, 2017
Pfizer, Direct Buyers Duel For Quick Wins In Celebrex Suit
Pfizer and a proposed class of direct purchasers who allege the drugmaker used fraudulent patents to delay generic-drug competition for its Celebrex painkiller filed dueling motions for summary judgment in Virginia federal court Tuesday about whether Pfizer was wrongly reissued an invalid patent.
-
May 25, 2017
Pfizer Says Expert Testimony In Celebrex Suit Unreliable
Pfizer asked a Virginia federal judge Wednesday to exclude expert testimony supporting the certification of a class of direct purchasers who allege the drugmaker used fraudulent patents to delay generic-drug competition for its Celebrex painkiller, saying the testimony is not reliable.
-
April 06, 2017
Celebrex Buyers Seek Class Cert. In Pfizer Antitrust Suit
Purchasers of popular painkiller Celebrex on Wednesday asked a Virginia federal court to certify as a class action its suit against Pfizer accusing the drug giant of using fraudulent patents to delay generic-drug competition and maintain supracompetitive prices for the drug.